Abstract
A 63-year-old woman with seropositive rheumatoid arthritis was successfully treated with auranofin for 12 months. Heavy proteinuria then developed and the drug was stopped. However, the proteinuria apparently became worse. This was later recognised to be a spurious effect due to the introduction of tolmetin. Renal biopsy showed a type I membranous glomerulonephropathy.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Ehrlich G. E., Wortham G. F. Pseudoproteinuria in tolmetin-treated patients. Clin Pharmacol Ther. 1975 Apr;17(4):467–468. doi: 10.1002/cpt1975174467. [DOI] [PubMed] [Google Scholar]
- Plaza J. J., Herrero G., Barat A., Loutaif J. J., Hernando L., Vallado P., Oliva H. Membranous glomerulonephritis as a complication of oral gold therapy. Ann Intern Med. 1982 Oct;97(4):563–564. doi: 10.7326/0003-4819-97-4-563. [DOI] [PubMed] [Google Scholar]
- Revach M., Freed R. L., Ehrlich G. E. Reversible proteinuria as a complication of oral gold therapy. Arthritis Rheum. 1979 Dec;22(12):1417–1418. doi: 10.1002/art.1780221223. [DOI] [PubMed] [Google Scholar]
- Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]